Psoriatic Arthritis
Conference Coverage
VIDEO: Could a deep Koebner phenomenon trigger psoriatic arthritis?
Conference Coverage
Amgen’s termination of brodalumab stuns psoriasis world
News
Lasting ustekinumab benefits seen in psoriatic arthritis
Key clinical point: The effects of ustekinumab on joint and skin symptoms are maintained for up to 2 years in adult patients with PsA. Major...
Conference Coverage
Large-scale psoriasis study links trauma to arthritis
Key clinical point: Further research is needed before any clinical recommendations can be made based on these findings.
Conference Coverage
WCD: Psoriasis plus depression magnifies MI risk
Even mild psoriasis plus comorbid depression is associated with a greater risk of acute MI than is either condition alone.
Conference Coverage
EULAR: Epigenetics points to anti-TNF efficacy in psoriatic arthritis
Key clinical point:If preliminary findings are confirmed, methylation level profiling could lead to the identification of patients who are not...
Conference Coverage
VIDEO: Predicting anti-TNF failure in psoriatic arthritis
Conference Coverage
WCD: Ustekinumab succeeds as switch agent in psoriasis
Of 65 psoriasis patients switched to ustekinumab after failing initial anti-TNF therapy, 47 (72%) achieved PASI 75 within 12 weeks.
Conference Coverage
WCD: Tofacitinib’s benefits for psoriasis persist for 2 years
Key clinical point: Oral tofacitinib showed sustained efficacy for moderate to severe plaque psoriasis at 24 months in a large ongoing phase III...
Conference Coverage
Anti-TNFs help psoriatic arthritis patients get back to work
Key clinical point: Work disability is a reversible outcome in psoriatic arthritis and improves significantly more with use of anti-TNF drugs than...